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Hidradenitis suppurativa (HS) is a chronic, recurrent, inflammatory disease of apocrine gland-bearing skin which affects
approximately 1–4% of the population. The disease is more common in women and patients of African American descent and
approximately one-third of patients report a family history. Obesity and smoking are known risk factors, but associations with
other immune disorders, especially inflammatory bowel disease, are also recognized. The pathogenesis of HS is poorly understood
and host innate or adaptive immune response, defective keratinocyte function, and the microbial environment in the hair follicle
and apocrine gland have all been postulated to play a role in disease activity. While surgical interventions can be helpful to reduce
disease burden, there is a high recurrence rate. Increasingly, data supports targeted immune therapy forHS, and longitudinal studies
suggest benefit from these agents, both when used alone and as an adjunct to surgical treatments. The purpose of this review is to
outline the current data supporting use of targeted immune therapy in HS management.
1. Introduction
Hidradenitis suppurativa (HS) is a chronic, recurrent, inflam-
matory disease of the apocrine sweat glands, characterized
by recurrent abscessing inflammation [1]. The prevalence of
HS is estimated at 1–4% in young adults [2–5]. Women are
affected more commonly than men (with a female to male
ratio of 3 : 1), and the disease is more common in African
Americans (AA) [6]. Patients with HS develop inflammatory
nodules, abscesses, and sinus tracts around the apocrine
glands, and increasing evidence points to an immune basis
for this disease [7].
The Hurley staging system (Table 1) is a three-stage clas-
sification system developed for assessing extent and severity
of HS, and in particular for identifying patients who need
surgical intervention [1, 8]. Until now, surgery has been a
mainstay of HS management, and surgery remains the first-
line therapy for patients with extensive Hurley stage III dis-
ease [9]. Studies show that, in severe disease, the best results
are achieved with wide local excision [10–12], but even with
extensive surgical intervention HS often recurs and this has
led to the recent interest in the use of adjunctive biologic
therapy in the management of HS [13–15].
While several risk factors including obesity and smoking
are known to be associated with disease activity in HS, the
molecular drivers of HS are unknown and are actively being
investigated [16]. Host innate or adaptive immune response
[7], defective keratinocyte function [1], and the microbial
environment in the hair follicle and apocrine gland [17] have
all been postulated to play a role in disease activity. Recent
studies suggest that tumor necrosis factor 𝛼 (TNF𝛼) is
elevated in active lesions. In addition, interferon-gamma
(IFN-𝛾) has been shown to be elevated in lesion effluent [18],
and suppression of IL22 [19] along with the IL12/23 pathways
is thought to play a role in pathogenesis [20, 21].
The purpose of the current manuscript is to review the
data supporting the use of the currently available immuno-
logic therapies for HS and to provide an update on novel
immune mechanisms under investigation in HS.
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Table 1: Hurley staging system.
Stage
0 No active HS
I Localized abscess, no sinus tracts
II Recurrent abscesses with sinus tracts and scarring,single or multiple widely separated lesions
III Diffuse involvement with multiple interconnected sinustracts and abscesses
2. Currently Available Immune Therapies
2.1. Antibiotics. Antibiotics have been advocated as first-line
therapy for HS for many years [1]. However, routine cultures
of HS lesions often fail to identify infection or identify only
normal skin flora [22].
Recent use of next-generation sequencing techniques
using 16S and 18S ribosomal RNA to identify microbial
profiles of HS lesions has shown that there are differences
between lesional and nonlesional HS skin [22], with the
microbiome of lesional skin often demonstrating Corynebac-
terium species and Porphyromonas and Peptoniphilus species.
Porphyromonas and Peptoniphilus species were not detected
in healthy controls. In contrast, healthy skin showed a rela-
tively higher abundance of Propionibacterium species, indi-
cating that dysbiosis of the cutaneous microbiome may play
a role in HS [22].
Clinically it is acknowledged that while antibiotics play a
role in the management of HS [23, 24], their efficacy is often
short-lived. Antibiotic resistance, along with complications
from chronic antibiotic use, is a concern. In parallel with
investigations targeting immune pathways in HS, the inter-
play of the immune response with the microbiome should be
considered. In particular biofilm formation, which is known
to be associated with delayed healing in chronic wounds [25,
26], may play a role in advanced disease. Biofilms have been
shown to be present in established HS lesions [27], although
they are less prominent in early lesions. Further investigation
into biofilms in HS, and in particular antimicrobial peptide
pathways that assist with microbial clearance, may identify
novel therapeutic pathways in the management of HS [28–
31].
2.2. SteroidTherapy. Glucocorticoids are naturally occurring
hormones that have been used since the 1950s as anti-
inflammatory therapy for immune mediated diseases [32].
Glucocorticoid receptors are present in the cytoplasm of
almost all human cells. Upon binding to the glucocorticoid
domain the receptor translocates to the nucleus and binds to
glucocorticoid response elements in DNA, resulting in tran-
scription of steroid responsive genes. Glucocorticoids have
very wide-ranging clinical effects due to their potential to
increase transcription of a variety of cytokines, chemokines,
and inflammatory adhesion molecules [33, 34].
In the management of HS, intralesional steroid therapy
is often used to treat isolated nodules (e.g., triamcinolone
(3–5mg) injected into the nodules); however, there is min-
imal data to support its use in patients with extensive disease
[24, 35]. Similarly, while systemic corticosteroids in HS are
often advocated, there are no randomized controlled trials
to support their use, and due to the wide-ranging actions of
steroids, side effects limit their role in HS [24]. In a study
investigating low dose systemic prednisone as an adjunct to
other therapies there was some benefit, but it was largely seen
in the patientswho received steroids in conjunctionwith anti-
TNF-𝛼 agents [36].
2.3. Therapies Blocking Tumor Necrosis Factor-𝛼. TNF-𝛼 is a
central cytokine that regulates immune responses in several
inflammatory diseases.
Agents blocking TNF-𝛼 have been marketed for many
years for the treatment of rheumatoid arthritis, Crohn’s
disease, and other inflammatory diseases. Several anti-TNF-𝛼
agents have been utilized in the treatment of HS. Infliximab
(Remicade) is a chimeric monoclonal antibody that binds
soluble and cell-boundTNF-𝛼 and thus inhibits the actions of
circulating TNF-𝛼while also inducing apoptosis in cells with
TNF-𝛼 bound to their receptor. Adalimumab (Humira) is
a fully human monoclonal antibody which binds the soluble
and transmembrane forms of TNF-𝛼. Etanercept (Enbrel) is
a fusion protein created by linking the extracellular binding
regions from two TNF-RII (p75) receptors to the FC portion
of human IgG1. It binds both soluble TNF-𝛼 and lymphotoxin
(TNF-𝛽).
Early trials of TNF-𝛼 inhibitors in HS were limited due
to challenges defining clinical outcome measures. Etaner-
cept was shown to be ineffective for HS [37]. However, a
small trial of infliximab therapy (𝑛 = 38) showed a 50%
reduction in baseline HS Severity Index Score in the treated
group compared to placebo along with statistically significant
improvements in Dermatology Quality of Life Index (DQLI),
and inflammatory markers [38]. Infliximab has never been
through rigorous phase II and phase III studies for HS and
thus does not have regulatory approval for HS. However, the
results of this and other early studies [39, 40] suggest that
infliximab is effective inHS [41]. Based on data frompharma-
cokinetic studies, the addition of methotrexate to infliximab
increases patient exposure to infliximab by approximately
30%, and thus many rheumatologists use these agents in
combination to increase the efficacy from infliximab partic-
ularly in the HS patients who have concurrent inflammatory
arthritis.
Adalimumab has been more thoroughly studied in phase
II and two phase III clinical trials. Using the novel endpoint
of the Hidradenitis Suppurativa Clinical Response (HiSCR)
defined as a 50% reduction in active nodule (AN) count
without increase in abscesses or draining fistulae, the PIO-
NEER I and II studies were able to demonstrate efficacy of
adalimumab at a dose of 40mg weekly subcutaneously for
HS. It should be noted that these studies were conducted
in a predominantly Caucasian population, excluded patients
with more severe Hurley stage III disease, and also excluded
patients undergoing surgery or receiving concurrent opiate
analgesia. Longitudinal studies investigating observational
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cohorts of HS patients that are more representative of
the HS population seen in the United States are ongo-
ing.
3. Novel Immune Pathways and Therapies
Being Investigated for HS
3.1. Phosphodiesterase 4 (PDE4). Apremilast (Otezla) is a
small molecule selective inhibitor of phosphodiesterase 4
(PDE4). Inhibition of PDE4 impacts cellular cyclic AMP
production and thus reduces TNF-𝛼 production and secon-
darily reduces IL17 and IL23while increasing IL10.Developed
and FDA approved as an oral agent specifically for use in
psoriasis and psoriatic arthritis, this agent has been utilized
in small case series of patients with HS with some efficacy
[42].
3.2. IL12/23 Pathways. The IL12/23 pathway is implicated
in HS based on small studies demonstrating expression of
IL12/23 in macrophages infiltrating HS lesional skin [43] and
infiltration of theHS dermis by IL17 producing T-helper cells.
Additionally, single nucleotide polymorphisms in the IL12
receptor beta-1 impact the clinical phenotypes of HS [44].
Ustekinumab (Stelara) is a human monoclonal antibody
which targets the common p40 subunit of IL12 and IL23,
preventing receptor binding and T cell activation. Ustek-
inumab is FDA approved for psoriasis, psoriatic arthritis,
and Crohn’s disease. Case reports have demonstrated some
benefit of ustekinumab in HS [45–47].
3.3. IL-1 Pathways. Anakinra (Kineret) is a recombinant
IL-1 receptor antagonist which inhibits the biologic activity
of IL-1 by competitively binding to the IL-1 receptor [48].
This agent was originally developed for the treatment of
rheumatoid arthritis but has more recently been adopted
for use in autoinflammatory syndromes including familial
Mediterranean fever and adult onset Still’s disease. Use of
IL-1 receptor antagonist therapies in HS have had mixed
results with some studies showing lack of efficacy [49, 50],
but small case series and a recent randomized controlled
trial have shown efficacy in moderate to severe HS [51,
52]. In this double-blind randomized trial, anakinra efficacy
correlates with alterations in cytokine production by PBMC,
with increased production of IFN-𝛾 in the placebo arm
and increased IL-22 in the anakinra treated group. These
observations correlate with studies investigating cytokine
production in HS lesion tissue and effluent in which IFN-𝛾
has been shown to be elevated in active disease [18], and IL-
22 production is reduced [19], providing further evidence that
targeting biologic response pathways inHS can provide novel
therapeutic options for this disease.
3.4. Complement Pathways. Another pathway that has gen-
erated interest as a potential target for novel HS therapy is
the complement pathway, which has been shown to be active
in patients with HS [53]. An open label phase II study is
currently underway in Greece to investigate the safety of
the complement inhibitor IFX-1 in patients with moderate
to severe HS (NCT 03001622). The results of this study are
eagerly awaited, given its potential to add to the therapeutic
armamentarium in HS.
3.5. Antimicrobial Peptide Production. Abnormalities in ker-
atinocyte antimicrobial peptide (AMP) production may also
contribute to defective keratinocyte function and impaired
microbial clearance seen in HS [28–31]. These observations
are further supported by the data indicating that IL-22 pro-
duction is reduced in active disease and increases in response
to therapy [54]. In vitro data investigating keratinocyte
function in HS has corroborated this finding, demonstrating
reduced IL-22 release from keratinocytes harvested from
HS lesions compared to those from healthy skin. IL-22 is a
member of the IL-10 family of cytokines which play a role
in cutaneous innate immunity and stimulate antimicrobial
peptide (AMP) production. As the role of AMP in HS and
cytokines driving AMP production are further elucidated,
agents targeting the AMP pathways may represent novel
therapies for this disease.
4. Recommendations on Timing of
Immune Therapies Relative to Surgical
Interventions in HS
Patients with severe Hurley stage III disease are often
excluded from clinical trials of biologic agents because of
concerns that initiating immunosuppressive therapy without
surgical intervention carries the risk of disseminating infec-
tion. Studies show that wide local excision surgery is often the
most effective way to rapidly improve the quality of life for
patients with Hurley stage III disease [10]. However, a series
of recent studies suggest that patients treated with adjuvant
biologic therapy after radical resection of HS demonstrated
lower rates of recurrence and disease progression, as well
as longer disease-free interval [13]. Data from the Wound
Etiology andHealing-Hidradenitis Suppurativa (WE-HEAL-
HS) study has shown that combining biologic immuno-
suppression therapy with wide local excision surgeries is
more effective than either intervention alone, and data
suggests that timing of biologic therapy relative to surgery
does not alter the synergistic impact of these interventions
[55].
5. Long Term Impact of Uncontrolled
Inflammation in HS
Population based studies show that HS is associated with
a significantly increased risk of adverse cardiovascular out-
comes and all-cause mortality independent of confounders
[56]. It has been postulated that, similar to the association
seen in rheumatoid arthritis and other chronic inflammatory
conditions, the increased risk of cardiovascular disease may
be explained by uncontrolled inflammation. These observa-
tions further support the need for identifying more effective
therapies for HS and for longitudinal outcomes studies in
HS to investigate the impact of immune suppression in this
patient population.
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6. Conclusions
The role of the immune system in driving HS is increasingly
recognized and various therapies are under investigation for
efficacy as treatment for HS. Based on data from randomized
controlled clinical trials, the TNF𝛼 inhibitor adalimumab
recently received orphan drug designation for HS. As new
immune pathways driving disease pathogenesis are recog-
nized, there is a significant need for ongoing clinical studies
investigating adjunctive immune therapies in HS.
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